Cargando…

No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect

The T allele of TCF7L2 rs7903146 is a common genetic variant associated with type 2 diabetes (T2D), possibly by modulation of incretin action. In this study, we evaluated the effect of the TCF7L2 rs7903146 T allele on the incretin effect and other glucometabolic parameters in normal glucose tolerant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathiesen, David S, Bagger, Jonatan I, Hansen, Katrine B, Junker, Anders E, Plamboeck, Astrid, Harring, Signe, Idorn, Thomas, Hornum, Mads, Holst, Jens J, Jonsson, Anna E, Hansen, Torben, Vilsbøll, Tina, Lund, Asger, Knop, Filip K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774769/ https://www.ncbi.nlm.nih.gov/pubmed/33252353 http://dx.doi.org/10.1530/EC-20-0471

Ejemplares similares

Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
por: Mari, Andrea, et al.
Publicado: (2013)

Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat
por: Mathiesen, David S., et al.
Publicado: (2021)

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes
por: Sonne, David P, et al.
Publicado: (2014)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Hansen, Katrine B, et al.
Publicado: (2010)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

No effect of the turmeric root phenol curcumin on prednisolone-induced glucometabolic perturbations in men with overweight or obesity
por: Hellmann, Pernille H, et al.
Publicado: (2023)

Role of fasting duration and weekday in incretin and glucose regulation
por: Clemmensen, Kim K B, et al.
Publicado: (2020)

Role of fasting duration and weekday in incretin and glucose regulation
por: Clemmensen, Kim K B, et al.
Publicado: (2021)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
por: Subramanian, Vijaya, et al.
Publicado: (2022)

Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study
por: Idorn, Thomas, et al.
Publicado: (2013)

The effect of curcumin on hepatic fat content in individuals with obesity
por: Hellmann, Pernille H., et al.
Publicado: (2022)

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
por: Knop, Filip K, et al.
Publicado: (2014)

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
por: Hædersdal, Sofie, et al.
Publicado: (2020)

Hepatic microbiome in healthy lean and obese humans
por: Suppli, Malte Palm, et al.
Publicado: (2021)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes
por: Christensen, Mikkel B, et al.
Publicado: (2020)

Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes
por: Mandøe, Mette Johannsen, et al.
Publicado: (2018)

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
por: Foghsgaard, Signe, et al.
Publicado: (2013)

Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses
por: Engelbrechtsen, Line, et al.
Publicado: (2018)

Response to Letter to the Editor from McKee and McGill: “Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring”
por: Juel, Caroline T B, et al.
Publicado: (2021)

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
por: Christensen, Alexander S., et al.
Publicado: (2020)

Mechanism‐Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake
por: Guiastrennec, B, et al.
Publicado: (2016)

Incretin hormones and the satiation signal
por: Holst, J J
Publicado: (2013)

Incretin-Based Therapies: Viewpoints on the way to consensus
por: Nauck, Michael. A., et al.
Publicado: (2009)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
por: Vedtofte, Louise, et al.
Publicado: (2020)

Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty
por: Plamboeck, Astrid, et al.
Publicado: (2013)

Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes
por: Fotheringham, Amelia K., et al.
Publicado: (2020)

High levels of mannose-binding lectin are associated with lower pulse wave velocity in uraemic patients
por: Hornum, Mads, et al.
Publicado: (2014)

Pleiotropic effects of incretins
por: Gupta, Vishal
Publicado: (2012)

Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism
por: Mikkelsen, Kristian H., et al.
Publicado: (2015)

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial
por: Johansen, Nicklas Järvelä, et al.
Publicado: (2018)

The incretin effect in critically ill patients: a case–control study
por: Nielsen, Signe Tellerup, et al.
Publicado: (2015)

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial
por: Sidelmann Christensen, Alexander, et al.
Publicado: (2018)

Effect of Glycemia on Plasma Incretins and the Incretin Effect During Oral Glucose Tolerance Test
por: Salehi, Marzieh, et al.
Publicado: (2012)

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
por: Vilsbøll, Tina, et al.
Publicado: (2012)

Incidental finding of non-alcoholic steatohepatitis-cirrhosis
por: Adrian, Therese, et al.
Publicado: (2022)

The Role of Incretins on Insulin Function and Glucose Homeostasis
por: Holst, Jens Juul, et al.
Publicado: (2021)

Understanding the Cardiovascular Effects of Incretin
por: Yoon, Ji Sung, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_5idu5iennppmlcg52tlofq14f1